Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Neurocrine (NBIX) and Tarsus Pharmaceuticals (TARS)
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $67
Tarsus Launches "Your Mitey Problem," the First Direct-to-Consumer TV Campaign for XDEMVY (Lotilaner Ophthalmic Solution) 0.25%
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Oppenheimer analyst Francois Brisebois maintains $Tarsus Pharmaceuticals(TARS.US)$ with a buy rating, and maintains the target price at $63.According to TipRanks data, the analyst has a success rate
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price In Tune With Revenues
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Barclays analyst Balaji Prasad maintains $Tarsus Pharmaceuticals(TARS.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 44.9%
Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues
Earnings Call Summary | Tarsus Pharmaceuticals(TARS.US) Q2 2024 Earnings Conference
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
Tarsus Pharmaceuticals Analyst Ratings
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating
Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $60 From $63
Express News | Tarsus Pharmaceuticals Inc : Guggenheim Raises Target Price to $75 From $67
Tarsus Pharmaceuticals GAAP EPS of -$0.88 Beats by $0.08, Revenue of $40.81M Beats by $8.76M
Tarsus Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results.
Earnings Flash (TARS) TARSUS PHARMACEUTICALS Reports Q2 Loss $-0.88, Vs. Street Est of $-0.80
Tarsus Pharmaceuticals | 10-Q: Q2 2024 Earnings Report